Ambalal Sarabhai Enterprises Limited (AMBALALSA) Financial History

Name: Ambalal Sarabhai Enterprises Limited (AMBALALSA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Ambalal Sarabhai Enterprises Limited (AMBALALSA) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Ahmedabad, India. Its market capitalization is roughly ₹3 billion. In the fiscal year ended 2026-03-31, AMBALALSA reported ₹2.0B in revenue and ₹178M in net income.

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally.

Interactive charts & full statements →

AMBALALSA Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹2.0B	₹2.0B	₹1.7B	₹1.7B
Gross Profit	₹743M	₹724M	₹642M	₹622M
Operating Income (EBIT)	₹163M	₹92M	₹52M	₹71M
Net Income	₹178M	₹49M	₹57M	₹114M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMBALALSA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹436M	₹655M	₹520M	₹444M	₹470M	—	—
Gross Profit	₹218M	₹256M	₹218M	₹187M	₹237M	—	—
Operating Income (EBIT)	₹52M	₹46M	₹31M	(₹6M)	₹90M	—	—
Net Income	₹40M	₹65M	₹31M	(₹6M)	₹82M	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AMBALALSA Free Cash Flow History

AMBALALSA Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹2.8B	₹2.7B	₹2.5B	₹2.5B	—
Total Liabilities	₹1.2B	₹1.3B	₹1.1B	₹1.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMBALALSA viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

0719 · Shandong Xinhua Pharmaceutical Company Limited — HK$4 billion
AAREYDRUGS · Aarey Drugs & Pharmaceuticals Limited — ₹3 billion
HIK · Hikma Pharmaceuticals PLC — £3 billion
SFZN · Siegfried Holding AG — CHF 3 billion
MEDICO · Medico Remedies Limited — ₹3 billion
1349 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. — HK$3 billion
2552 · Hua Medicine (Shanghai) Ltd. — HK$2 billion
NECLIFE · Nectar Lifesciences Limited — ₹2 billion

← AMBA All “A” companies AMBER →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.